COVID-19 Resource Center

COVID-19 Resource Center

Source: Press Release

Disclosures: Bancel is CEO of Moderna.
August 05, 2021
1 min read

Moderna COVID-19 vaccine 93% effective, ‘durable’ at 6 months, company says

Source: Press Release

Disclosures: Bancel is CEO of Moderna.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Moderna has announced that its COVID-19 vaccine was 93% effective, with “durable” efficacy lasting at least 6 months after administration of the second dose.

The company also said that it tested three booster candidates, which showed “robust antibody responses to COVID-19 variants of concern.”

Source: Adobe Stock.
Moderna said its COVID-19 vaccine was effective up to 6 months after administration of the second dose.
Photo source: Adobe Stock

The data on the Moderna vaccine’s durability are from a final analysis of the phase 3 COVE study, according to a press release. The company said it has begun the rolling submission process for a Biologics License Application for its COVID-19 vaccine, and it anticipates completing the process sometime this month.

Regarding Moderna’s booster candidates — the emergency-use-authorized mRNA-1273 and the investigational mRNA-1273.351 and mRNA-1273.211 — the company said a phase 2 study investigating a 50 µg dose of each product revealed strong responses against the wildtype D614G COVID-19 strain and the gamma, beta and delta variants.

“Neutralizing antibody levels following the boost approached those observed after primary vaccination with two doses of 100 µg of mRNA-1273,” Moderna said in the press release. “These data have been submitted to a peer-reviewed journal for publication.”

Moderna CEO Stéphane Bancel said in the press release that he was “pleased” with the COVID-19 vaccine results and indicated the company will remain “vigilant” against the delta variant.

Several studies analyzing Moderna’s COVID-19 vaccine response in children and adolescents aged 6 months to 17 years, as well as a “next-generation” COVID-19 vaccine, remain ongoing, the company said.